- All News
- In the News
- Press Releases
A commercial rapid host-response test in COVID-19 severity stratification and triage
In a late-breaker presentation onsite, Immunexpress collaborators at Hospital Foch, France evaluated the performance of SeptiCyte® RAPID using patient samples from COVID-19 positive cases, in a study supported by Immunexpress partner Biocartis and the Biomedical Advanced Research and Development Authority (BARDA).
Immunexpress CEO To Present at the Virtual Biotech Showcase 2022
Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today that Chief Executive Officer, Rolland Carlson, Ph.D., to present a corporate update, accessible on-demand, at the virtual Biotech Showcase 2022 to be held Jan. 10-12 and Jan. 17–19, 2022. Dr. Carlson will present...
Addressing the challenge of early detection and appropriate intervention in suspected sepsis
Dr. Roy Davis, an intensivist and quality program consultant, describes the current challenges associated with diagnosing sepsis and how they might be addressed by a recently FDA-cleared one-hour host response test. He will cover clinical validation of the test and how it might fit in the clinical workflow, aligning with...
DNA Weekly: Discussing Sepsis Diagnosis with Immunexpress
Immunexpress is a molecular diagnostic company focused on improving outcomes for suspected sepsis patients. In this interview CEO Dr. Rollie Carlson discusses the company’s FDA-cleared sepsis diagnostic test and the value it brings to the healthcare system.
FDA Clears SeptiCyte® RAPID – The First One-Hour, Direct-from-Blood Sepsis Test
Fully automated diagnostic tool SeptiCyte® RAPID quantifies the relative expression levels of genes involved in a patient's immune response to infection to aid in a diagnosis in one hour for patients suspected of sepsis Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced...
Superior Sepsis Diagnostic Performance of SeptiCyte® RAPID Compared to Lactate and Procalcitonin Presented at IDWeek 2021
SeptiCyte® RAPID proved superior to routinely used diagnostic tools for the differentiation of sepsis from infection negative systemic inflammation SEATTLE, Sept. 29, 2021 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced a presentation, titled "Comparison of lactate, procalcitonin and a gene signature assay...
Comparison of Lactate, Procalcitonin and a Gene Signature Assay Alone or in Combination to Differentiate Sepsis from Infection Negative Systemic Inflammation in ICU Patients
Immunexpress to Present SeptiCyte® RAPID Comparative Data Against Lactate and Procalcitonin for Diagnosing Sepsis at IDWeek 2021
Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced a presentation demonstrating comparative data of SeptiCyte® RAPID, lactate, and procalcitonin in differentiating sepsis from infection negative systemic inflammation at IDWeek 2021, taking place virtually on Sept. 29 – Oct. 3, 2021. Details...
SeptiCyte RAPID is highlighted in this 10News First Brisbane interview. The country's largest pediatric sepsis study at the Queensland Children's Hospital is working on finding simple diagnostic blood tests for the 5,000 Australians a year and robs others of their limbs.
Immunexpress Announces SeptiCyte® RAPID Testing For Paediatric Sepsis
BRISBANE, Australia, Aug. 24, 2021 /PRNewswire/ -- Immunexpress, Pty Ltd, a molecular diagnostic company founded in Brisbane, today announced that the SeptiCyte® RAPID test will be evaluated in the diagnosis of paediatric sepsis in Queensland children. The testing is in part funded through a Federal Government's Medical Research Future Fund Genomic Health Futures Mission grant for...
Immunexpress Presents Data Supporting SeptiCyte® RAPID for COVID-19 Patient Triage as a Late-Breaking Abstract at ECCMID 2021
SEATTLE, July 9, 2021 – Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced a late-breaking presentation, titled “Use of SeptiCyte RAPID to assess the risk of ICU admission in COVID-19 patients” (ID#4984), demonstrating the performance of SeptiCyte® RAPID in triaging COVID-19 patients...